Advanced Search
LI Zechao, ZHOU Yong, LUO Shiqiao. Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 154-158. DOI: 10.3971/j.issn.1000-8578.2015.02.012
Citation: LI Zechao, ZHOU Yong, LUO Shiqiao. Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 154-158. DOI: 10.3971/j.issn.1000-8578.2015.02.012
shu

Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases

  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

More Information
  • Received Date: May 12, 2014
  • Revised Date: June 22, 2014
    Graphical Abstract
    • Abstract
  • Objective To analyze the clinical features of pancreatic cancer patients with liver metastasis and multimodality treatments, and to explore the impact of multimodality treatments on the prognosis of pancreatic cancer patients. Methods We retrospectively analyzed 64 pancreatic cancer patients with liver metastasis hospitalized in The First Affiliated Hospital of Chongqing Medical University from January 2009 to January 2012. Prognostic factors in clinical features and multimodality treatments were analyzed by Kaplan-Meier method and Cox regression model with SPSS19.0 software. Results The median survival time (MST) was 4 month. 6-month, 1-year and 2-year overall survival (OS) were 39.1%, 21.9% and 7.8% respectively. Univariate analysis revealed that there were significant differences in age, pain, anorexia, CA19-9, ALT and GGT levels, surgery, chemotherapy embolism/ transarterial chemotherapy, active treatment and multi-disciplinary treatment. Multivariate analysis showed that extrahepatic metastasis, pain, CA19-9, active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment were closely related to the survival and prognosis of patients. Conclusion In pancreatic cancer patients with liver metastases, pain, CA19-9≥1 000 u/ml and extrahepatic metastases at diagnosis are adverse prognostic factors. Active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment could improve the quality of life and prolong the survival time of pancreatic cancer patients with liver metastases.
    • FullText(HTML)
    • References (21)
  • [1]
    Liu FY, Wang MQ, Duan F, et al. Hepatic artery chemoembolization in patients with liver metastasis from pancreatic carcinoma[J]. Zhongguo Zhong Liu Lin Chuang, 2012, 39(6): 331-5. [刘凤 永,王茂强,段峰,等. 胰腺癌肝转移的介入治疗[J].中国肿瘤临 床,2012,39(6):331-5.]
    [2]
    Katopodis O, Souglakos J, Stathopoulos E, et al. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [J]. Cancer Chemother Pharmacol, 2014, 74(2):333-40.
    [3]
    Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges [J]. Nat Rev Clin Oncol, 2010, 7( 3):163-72.
    [4]
    Tas F, Sen F, Keskin S, et al. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival [J]. Mol Clin Oncol, 2013(1):788-92.
    [5]
    Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer[J]. J Clin Gastroenterol, 2008, 42 (1):86-91.
    [6]
    Liu LX, Ji W, Wang JH, et al. A retrospective analysis on survival factors of transarterial chemoembolization for patients of pancreatic carcinoma with liver metastasis [J]. Fu Dan Xue Bao(Yi Xue Ban), 2011, 38(2): 101-6.[刘凌晓, 姬巍, 王建华, 等. 胰腺癌肝转移患者综合性介入栓塞治疗生存情况的回顾性分 析[J] 复旦学报（医学报）, 2011, 38(2):101-6.]
    [7]
    Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase i/ii trial [J]. J Clin Oncol, 2011, 29(34): 45 49-50.
    [8]
    Ouyang HQ, Huang JQ, Liu LM, et al. Clinical analysis of multimodality treatment for 164 cases of pancreatic cancer with liver metastases[C].The First TCM and Western Medicine Oncology Forum in 2009 by Doctors and Young and Middle-aged Clinicians, 2011: 211-3.[欧阳华强,黄建琴,刘鲁明,等.多学科综 合治疗胰腺癌肝转164例临床分析[C].2009年首届全国中西医 肿瘤博士及中青年医师论坛, 2011: 211-3.]
    [9]
    Zhao J, Hu Y, Liao Q, et al. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer[J]. World J Gastroenterol, 2014, 20(19): 5875-80.
    [10]
    Yang GY, Malik NK, Chandrasekhar R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer [J]. J Gastrointest Oncol, 2013, 4(4): 361-9.
    [11]
    Ni QX, Yu XR, Liu L. Discussion for the clinical definition of pancreatic cancer in China [J]. Zhongguo Ai Zheng Za Zhi, 2012, 22 (2):81-7.[倪泉兴, 虞先溶, 刘亮. 中国胰腺癌临床诊断标准的 探讨[J] 中国癌症杂志, 2012, 22(2): 81-7.]
    [12]
    Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma [J]. Ann Surg Oncol, 2007, 14 (1): 118-27.
    [13]
    Lorente-Herce JM, Parra-Membrives P, Díaz-Gómez D. Increased survival after resection of pancreatic cancer liver metastases[J]. Cir Esp, 2013, 91(6): 390-2.
    [14]
    SK S, Burkert B, AM C, et al. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy [J]. HPB Surg, 2010, 2010: 579672.
    [15]
    Azizi A, Naguib NN, Mbalisike E, et al. Liver metastases of pancreatic cancer : role of repeti tive transar ter ial chemoembolization (TACE) on tumor response and survival [J]. Pancreas, 2011, 40(8): 1271-5.
    [16]
    Klimant E, Markman M, Albu DM. Clinically meaningful response to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer [J]. Case Rep Oncol, 20 13, 6(1): 72-7.
    [17]
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [J]. N Engl J Med, 20 11, 364(19): 1817-25.
    [18]
    Sung HY, Jung SE, Cho SH, et al. Long-term outcome of highintensity focused ultrasound in advanced pancreatic cancer [J]. Pancreas, 2011, 40(7): 1080-6.
    [19]
    De Jong MC, Farmell MB, Sclabs G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis [J]. Ann Surg, 20 10, 252(1):142-8.
    [20]
    Xia SA, Wang J, Che LP, et al. Clinical significance of threedimensional conformal technique treatment for locally advanced pancreatic cancer[J].Zhongguo Yi Yao Dao Bao, 2012, 9( 35):75-6,80.[夏士安, 王佳, 车莉萍, 等. 探讨三维适行放射治 疗在晚期胰腺癌中的临床意义[J]. 中国医药导报, 2012, 9(35): 75 -6,80.]
    [21]
    Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma. The Mayo Clinic experience(1975-2005) [J]. J Clin Oncol, 2008, 26 (21) : 3511-6.
    • Related Articles

  • Related Articles

    [1]TONG Jinlong, WANG Haiyu, TIAN Xiaoqiang, LI Ying, LU Shihui, YE Wei. Prognostic Value of Radiation-Induced Lymphopenia in Patients with Unresectable Primary Hepatocellular Carcinoma Receiving Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2024, 51(12): 1007-1014. DOI: 10.3971/j.issn.1000-8578.2024.24.0096
    [2]WANG Runmei, YANG Hao, YU Rong, WANG Zhenfei, WU Yu, LI Hong, HU Yue. Prophylactic Dexamethasone on Pain Flare in Spine Metastasis Stereotactic Body Radiotherapy and Hypofractionated Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1096-1100. DOI: 10.3971/j.issn.1000-8578.2021.21.0298
    [3]LIN Jian, WANG Haibo, SHEN Feng. Advance in Therapeutic Targets of Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 224-228. DOI: 10.3971/j.issn.1000-8578.2021.20.1248
    [4]XIAO Jincheng, GUO Leiming, KANG Xinxin, BAI Qiwen, ZHANG Junling, LI Jing. Comparison of Efficiency and Safety Between Radiofrequency Ablation and Stereotactic Body Radiotherapy on Primary Small Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 831-835. DOI: 10.3971/j.issn.1000-8578.2017.17.0613
    [5]ZHANG Jiangzhou, LONG Zhixiong. Microwave Ablation Combined with Stereotactic Radiotherapy for Primary and Recurrent Hepatocellular Carcinoma after Interventional Treatment[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 649-652. DOI: 10.3971/j.issn.1000-8578.2014.06.031
    [6]WU Weizhang, CHANG Dongshu, ZHU Fuhai, WANG Yong. Dose Distribution of Body Gamma Rays Radiotherapy for Multiple Pulmonary Metastatic Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 391-394. DOI: 10.3971/j.issn.1000-8578.2014.04.024
    [7]WANG Peng, PAN Mian-shun, HUANG Yong. Effecting Observation of Stereotactic Radiotherapy Combined with Chemotherapy for Postoperative Local Recurrent Rectal Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(07): 524-526. DOI: 10.3971/j.issn.1000-8578.2282
    [8]ZHANG Xin-hua, LUO Ding-tai, YANG Zi-wan, et al, . Hepatic artery intubatton chemotherapy and radiotherapy alternately to treat primary liver cancer[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 73-74. DOI: 10.3971/j.issn.1000-8578.134
    [9]XIAO Hong, PANG Xue-li, TAN Chong-fu, et al, . Preliminary Clinical Study of the Effect of Stereotactic Radiotherapy Boost Following Conventional Radiotherapy on Local Control Rate of Primary Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 405-406. DOI: 10.3971/j.issn.1000-8578.958
    [10]WANG Ying-xuan, PAN Long-sheng, ZHANG Ji, et al, . Stereotactic Radiosurgery for Pituitary Tumors[J]. Cancer Research on Prevention and Treatment, 2001, 28(02): 138-141. DOI: 10.3971/j.issn.1000-8578.2603

Catalog

    Get Citation
    PDF
    XML
    Article views (1621) PDF downloads (1134) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：12456544 Visits today：5411

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return